Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression

Cardiovascular Drugs and Therapy

Volumn 21, Issue 3, 2007, Pages 155-160

  Saegusa, Seiichiro ^a   Fei, Yu ^a   Takahashi, Takashi ^a   Sumino, Hiroyuki ^b   Moriya, Junji ^a   Kawaura, Ken ^a   Yamakawa, Jun Ichi ^a   Itoh, Tohoru ^a   Morimoto, Shigeto ^a   Nakahashi, Takeshi ^a   Iwai, Kunimitsu ^a   Matsumoto, Masayuki ^a   Kanda, Tsugiyasu ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Acute heart failure; Adiponectin; Candesartan; Myocarditis

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; MESSENGER RNA; PLACEBO;

ACUTE HEART FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; C3H MOUSE; CIRCULATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG MECHANISM; ENCEPHALOMYOCARDITIS VIRUS; HEART INJURY; HEART MUSCLE INJURY; HEART PROTECTION; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MODIFICATION; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS MYOCARDITIS;

ADIPONECTIN; ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HEART; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICE; MICE, INBRED C3H; MYOCARDITIS; MYOCARDIUM; ORGAN SIZE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TETRAZOLES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES; WEIGHT GAIN;

EID: 34249310285     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6024-4     Document Type: Article

References (24)

1. Nimata M, Kishimoto C, Yuan Z, Shioji K. Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 2004;259:217-22.
2. Kanda T, McManus JE, Yang DC, McManus BM, Imai S, Suzuki T, et al. Modification of viral myocarditis in mice by interleukin-6. Circ Res 1996;78:848-58.
3. Araki M, Kanda T, Imai S, Suzuki T, Murata K, Kobayashi I. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. J Cardiovasc Pharmacol 1995;26:61-5.
4. Shirai K, Watanabe K, Ma M, Wahed MI, Inoue M, Saito Y, et al. Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. Mol Cell Biochem 2005;269:137-42.
5. Wu L, Iwai M, Nakagami H, Li Z, Chen R, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001;104:2716-21.
6. Lorenzo O, Ruiz-Ortega M, Suzuki Y, Ruperez M, Esteban V, Sugaya T, et al. Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol 2002;13:1162-71.
7. Berthonneche C, Sulpice T, Tanguy S, O'Connor S, Herbert JM, Janiak P, et al. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats. Cardiovasc Drugs Ther 2005;19:251-9.
8. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000;102:1296-301.
9. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
10. Yamamoto K, Shioi T, Uchiyama K, Miyamoto T, Sasayama S, Matsumori A. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. J Am Coll Cardiol 2003;42:2000-6.
11. Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, Kusaka K, et al. Angiotensin-II receptor antagonist alleviates non-alcoholic fatty liver in KKAy obese mice with type 2 diabetes. J Int Med Res 2006;34:297-302.
12. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, et al. Long-term angiotensin II AT(1) receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006;552:112-22.
13. Takahashi T, Saegusa S, Sumino H, Nakahashi T, Iwai K, Morimoto S, et al. Adiponectin, T-cadherin and tumor necrosis factor-alpha in damaged cardiomyocytes from autopsy specimens. J Int Med Res 2005;33:236-44.
14. Takahashi T, Yu F, Saegusa S, Sumino H, Nakahashi T, Iwai K, et al. Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. Int Heart J 2006;47:107-23.
15. Ishikawa Y, Akasaka Y, Ishii T, Yoda-Murakami M, Choi-Miura NH, Tomita M, et al. Changes in the distribution pattern of gelatin-binding protein of 28 kDa (adiponectin) in myocardial remodelling after ischaemic injury. Histopathology 2003;42:43-52.
16. Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994;90:2051-55.
17. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33.
18. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003;42:76-81.
19. Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-95.
20. Sun M, Dawood F, Wen WH, Chen M, Dixon I, Kirshenbaum LA, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial ruptureand left ventricular dysfunction. Circulation 2004;110:3221-8.
21. Yue P, Massie BM, Simpson PC, Long CS. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 1998;275:H250-8
22. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303-2312.
23. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-7.
24. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285:E1072-80.